Barinthus Biotherapeutics plc American Depositary Shares (BRNS) Stock Price, Quote & AI Analysis
Live BRNS stock price, real-time charts, AI-powered analysis, technical analysis, earnings insights, and market sentiment for Barinthus Biotherapeutics plc American Depositary Shares.
TradeVae provides AI-driven analysis and real-time market intelligence for Barinthus Biotherapeutics plc American Depositary Shares (BRNS), including price action, technical indicators, earnings performance, analyst sentiment, and risk-aware market context.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
Barinthus Biotherapeutics plc American Depositary Shares's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
Barinthus Biotherapeutics plc American Depositary Shares Overview
Company information
Company Overview
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.
Company Details
Technical Indicators
Key technical analysis metrics and indicators
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
Barinthus Biotherapeutics plc American Depositary Shares Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...